IQVIA Holdings Inc. (NYSE:IQV) Stake Increased by Siemens Fonds Invest GmbH

Siemens Fonds Invest GmbH increased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 973.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 21,345 shares of the medical research company’s stock after buying an additional 19,356 shares during the quarter. Siemens Fonds Invest GmbH’s holdings in IQVIA were worth $4,195,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently bought and sold shares of the company. JPMorgan Chase & Co. lifted its position in shares of IQVIA by 46.2% in the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after purchasing an additional 583,396 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its position in IQVIA by 1.0% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 5,434 shares of the medical research company’s stock worth $1,068,000 after buying an additional 56 shares in the last quarter. Pallas Capital Advisors LLC acquired a new stake in shares of IQVIA during the 4th quarter valued at $298,000. Fifth Third Wealth Advisors LLC grew its holdings in shares of IQVIA by 26.1% during the 4th quarter. Fifth Third Wealth Advisors LLC now owns 1,839 shares of the medical research company’s stock valued at $361,000 after acquiring an additional 381 shares in the last quarter. Finally, Sendero Wealth Management LLC increased its stake in shares of IQVIA by 25.4% in the fourth quarter. Sendero Wealth Management LLC now owns 45,221 shares of the medical research company’s stock worth $8,886,000 after acquiring an additional 9,153 shares during the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Mizuho lowered their target price on IQVIA from $210.00 to $190.00 and set an “outperform” rating on the stock in a research note on Thursday. BTIG Research cut IQVIA from a “buy” rating to a “neutral” rating in a research note on Monday, February 3rd. HSBC downgraded IQVIA from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $260.00 to $160.00 in a report on Friday, April 25th. Barclays decreased their target price on shares of IQVIA from $170.00 to $165.00 and set an “equal weight” rating for the company in a research report on Wednesday, May 7th. Finally, UBS Group cut their price target on shares of IQVIA from $255.00 to $185.00 and set a “buy” rating on the stock in a report on Wednesday, May 7th. Eight equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, IQVIA presently has an average rating of “Moderate Buy” and a consensus price target of $230.76.

IQVIA Trading Down 0.9%

Shares of IQV opened at $140.51 on Friday. The stock’s 50-day moving average price is $160.66 and its 200 day moving average price is $186.58. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The firm has a market capitalization of $24.31 billion, a price-to-earnings ratio of 18.73, a P/E/G ratio of 1.99 and a beta of 1.34. IQVIA Holdings Inc. has a 12-month low of $135.97 and a 12-month high of $252.88.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, May 6th. The medical research company reported $2.70 EPS for the quarter, beating analysts’ consensus estimates of $2.63 by $0.07. The business had revenue of $3.83 billion during the quarter, compared to analyst estimates of $3.77 billion. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. IQVIA’s revenue was up 2.5% on a year-over-year basis. During the same period in the prior year, the company posted $2.54 earnings per share. As a group, research analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.